147 related articles for article (PubMed ID: 26813510)
21. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
[TBL] [Abstract][Full Text] [Related]
22. Jolkinolide B inhibits RANKL-induced osteoclastogenesis by suppressing the activation NF-κB and MAPK signaling pathways.
Ma X; Liu Y; Zhang Y; Yu X; Wang W; Zhao D
Biochem Biophys Res Commun; 2014 Mar; 445(2):282-8. PubMed ID: 24491533
[TBL] [Abstract][Full Text] [Related]
23. Suppression of NF-kappaB increases bone formation and ameliorates osteopenia in ovariectomized mice.
Alles N; Soysa NS; Hayashi J; Khan M; Shimoda A; Shimokawa H; Ritzeler O; Akiyoshi K; Aoki K; Ohya K
Endocrinology; 2010 Oct; 151(10):4626-34. PubMed ID: 20810563
[TBL] [Abstract][Full Text] [Related]
24. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY
Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747
[TBL] [Abstract][Full Text] [Related]
25. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo.
Jimi E; Aoki K; Saito H; D'Acquisto F; May MJ; Nakamura I; Sudo T; Kojima T; Okamoto F; Fukushima H; Okabe K; Ohya K; Ghosh S
Nat Med; 2004 Jun; 10(6):617-24. PubMed ID: 15156202
[TBL] [Abstract][Full Text] [Related]
27. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption.
Xing L; Carlson L; Story B; Tai Z; Keng P; Siebenlist U; Boyce BF
J Bone Miner Res; 2003 Feb; 18(2):260-9. PubMed ID: 12568403
[TBL] [Abstract][Full Text] [Related]
28. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
29. IL-1 plays an important role in the bone metabolism under physiological conditions.
Lee YM; Fujikado N; Manaka H; Yasuda H; Iwakura Y
Int Immunol; 2010 Oct; 22(10):805-16. PubMed ID: 20679512
[TBL] [Abstract][Full Text] [Related]
30. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
31. Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-kappaB.
Li Y; Li A; Strait K; Zhang H; Nanes MS; Weitzmann MN
J Bone Miner Res; 2007 May; 22(5):646-55. PubMed ID: 17266397
[TBL] [Abstract][Full Text] [Related]
32. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
Ichikawa H; Murakami A; Aggarwal BB
Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
[TBL] [Abstract][Full Text] [Related]
33. Decitabine represses osteoclastogenesis through inhibition of RANK and NF-κB.
Guan H; Mi B; Li Y; Wu W; Tan P; Fang Z; Li J; Zhang Y; Li F
Cell Signal; 2015 May; 27(5):969-77. PubMed ID: 25683916
[TBL] [Abstract][Full Text] [Related]
34. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
[TBL] [Abstract][Full Text] [Related]
35. Role of nuclear factor-kappaB in the immune system and bone.
Jimi E; Ghosh S
Immunol Rev; 2005 Dec; 208():80-7. PubMed ID: 16313342
[TBL] [Abstract][Full Text] [Related]
36. Benzo[a]pyrene inhibits osteoclastogenesis by affecting RANKL-induced activation of NF-kappaB.
Voronov I; Li K; Tenenbaum HC; Manolson MF
Biochem Pharmacol; 2008 May; 75(10):2034-44. PubMed ID: 18396263
[TBL] [Abstract][Full Text] [Related]
37. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH
Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626
[TBL] [Abstract][Full Text] [Related]
38. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
[TBL] [Abstract][Full Text] [Related]
39. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
[TBL] [Abstract][Full Text] [Related]
40. Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation.
Ang ES; Yang X; Chen H; Liu Q; Zheng MH; Xu J
FEBS Lett; 2011 Sep; 585(17):2755-62. PubMed ID: 21835177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
